News
Videos
Conferences
Events
Resources
Subscribe

|Videos|January 31, 2016

Finding the Right Treatment Option

Episodes in this series

EP. 1 Freda's Story: Her Diagnosis of CRC

EP. 1 Freda's Story: Her Diagnosis of CRC

EP. 2 Interventional Radiologist's Role

EP. 2 Interventional Radiologist's Role

EP. 3 Considering a Second Opinion for Cancer Care

EP. 3 Considering a Second Opinion for Cancer Care

EP. 4 It Takes a Team to Treat Cancer

EP. 4 It Takes a Team to Treat Cancer

EP. 5 Treatment of Metastatic Colorectal Cancer

EP. 5 Treatment of Metastatic Colorectal Cancer

EP. 6 Clinical Trials for Cancer Treatment

EP. 6 Clinical Trials for Cancer Treatment

EP. 7 Improving Care For Patients

EP. 7 Improving Care For Patients

EP. 8 Freda: Managing Aggressive Treatment

EP. 8 Freda: Managing Aggressive Treatment

EP. 9 Finding the Right Treatment Option

EP. 9 Finding the Right Treatment Option

EP. 10 How to Pay for Treatment Options

EP. 10 How to Pay for Treatment Options

Newsletter

Stay up to date on cancer updates, research and education

Related Content

Dr. Kathie-Ann Joseph

The Power of Personalized Care in Breast Cancer Treatment

February 6th 2026

Carla Deschamps

How Mantras Impacted My Life During a Colon Cancer Journey

ByCarla Deschamps

February 6th 2026

Image of woman,

Pastina Bean Soup Supports Nutrition in Colorectal Cancer Care

BySpencer Feldman

February 4th 2026

breast cancer

NCCN Names Trodelvy a Preferred First-Line Treatment for Metastatic TNBC

February 4th 2026

The U.S. FDA has granted fast track status to pelareorep combination therapy for some KRAS-mutant, microsatellite-stable metastatic colorectal cancers: © stock.adobe.com.

Pelareorep Receives FDA Fast Track Status for KRAS-Mutant Colorectal Cancer

February 4th 2026

Trending on CURE

FDA Updates Safety Warnings for Common Chemotherapy Drugs

KTX-1001 Elicits Responses in Some With Multiple Myeloma

FDA Removes Use Limitation for Yescarta in Primary CNS Lymphoma

New Combination Treatment Approach Studied in Pancreatic Cancer

Biomarker-Free Relacorilant Combo Broadens Options in Ovarian Cancer